arrow_back Back to App

Faster FDA Review: Modernizing Human Cell and Tissue Product Regulations

This law aims to speed up and clarify the approval process for new therapies based on human cells and tissues (like regenerative medicine). It mandates the FDA to quickly respond to manufacturers' questions about product classification, potentially reducing the time it takes for treatments to reach the market. Citizens can expect clearer safety standards and potentially faster access to innovative medical treatments.
Key points
Establishes a 70-day deadline for the FDA to provide a preliminary, nonbinding opinion on how a specific cell or tissue product will be regulated.
Requires a public meeting to discuss and update key regulatory definitions, such as 'minimal manipulation' of tissue.
Mandates updating regulations within 12 months to reduce bureaucratic burdens on manufacturers while maintaining public health protection.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_8251
Sponsor: Rep. Crenshaw, Dan [R-TX-2]
Process start date: 2024-05-06
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-09-2025
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

The HCT/P Modernization Act of 2024

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_8251.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2024-05-06.

What are the main provisions?

Key points include:

  • Establishes a 70-day deadline for the FDA to provide a preliminary, nonbinding opinion on how a specific cell or tissue product will be regulated.
  • Requires a public meeting to discuss and update key regulatory definitions, such as 'minimal manipulation' of tissue.
  • Mandates updating regulations within 12 months to reduce bureaucratic burdens on manufacturers while maintaining public health protection.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Crenshaw, Dan [R-TX-2].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health